Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

Fig. 3

Time-course analysis of three representative TNBC PDXs. Low passage TNBC PDX tumor samples BCM-4664, BCM-2147, and BCM-3555 were transferred into the right mammary fat pad of mice for engraftment. Once tumors reached an average size of 100–200 mm3, mice were randomized (n ≥ 6 per group) and treated following the three 1-week cycle design, consisting of intraperitoneal IP injection three times/week of either formulation buffer (vehicle control) or Pan-HER (50 mg/kg). Mouse weight was recorded and tumor volumes measured and calculated, as described in “Methods”, twice weekly. Tumor volume fold change was calculated based on the baseline tumor volumes for each arm. Two-way ANOVA was used for statistical analysis. Arrows indicate the beginning (red arrow) and end (blue arrow) of treatment

Back to article page